Perrigo has changed its reporting segments to better align with the company’s organizational structure. Beginning with the fourth quarter of calendar year 2016, the Perrigo’s new reporting segments are: Consumer Healthcare Americas, Consumer Healthcare International, Prescription Pharmaceuticals, Specialty Sciences, and Other.

The businesses in the new organization structure of the new reporting segments are as follows: Consumer Healthcare Americas comprises the legacy US, Mexico, and Canada consumer healthcare business, including over-the-counter, contract, infant formula, and animal health categories; Prescription Pharmaceuticals comprises the legacy US prescription pharmaceuticals business; Specialty Sciences will continue to comprise royalties from Tysabri (natalizumab), a drug for treating multiple sclerosis marketed by Biogen; and Other will continue to comprise the legacy active pharmaceutical ingredients.

In addition, the Consumer Healthcare International segment comprises the legacy branded consumer healthcare segment and now includes consumer-focused businesses in the UK, Australia, and Israel, which were previously reported in the legacy Consumer Healthcare segment. This segment will also include Perrigo’s UK liquids licensed products business, which was previously reported in the Prescription Pharmaceuticals segment.

Source: Perrigo